Description
Bausch + Lomb Corporation’s Growth Surge: Can New Contact Lens Tech Grab A Larger Chunk Of The Market?
Bausch + Lomb recently held its third-quarter 2025 financial results presentation, highlighting several aspects of its performance and strategic focus. The company demonstrated notable growth across its various segments, driven by innovative product offerings and rigorous execution. Revenue for the quarter reached $1.281 billion, marking a 6% year-over-year increase. This growth was fueled by a diverse range of products, particularly in the Vision Care and Pharmaceuticals segments. A significant contributor to Bausch + Lomb’s revenue was the Pharmaceuticals division, which achieved considerable success with its dry eye treatment Miebo, bringing in $84 million for the quarter. The performance stood out despite the competitive market landscape. Additionally, the Vision Care segment, encompassing contact lenses and consumer health products, reported $736 million in revenue, reflecting robust growth. The Daily SiHy contact lenses saw a 24% increase in sales, underscoring the continued success of their innovative lens offerings.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures
Want unlimited access to our reports? Purchase our $99 annual subscription!
